# A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma

> **NCT02050321** · PHASE2 · TERMINATED · sponsor: **University of Arizona** · enrollment: 2 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** Acitretin
- **DRUG:** Vemurafenib

## Key facts

- **NCT ID:** NCT02050321
- **Lead sponsor:** University of Arizona
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-12
- **Primary completion:** 2014-12
- **Final completion:** 2015-07
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Pharmaceutical company pulled support for the trial.
- **Last updated:** 2018-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02050321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02050321, "A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02050321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*